Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Carol Stiff

- PMLiVE

BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

- PMLiVE

WHO report highlights impact of COVID-19 pandemic on non-communicable diseases

These diseases were responsible for an estimated 40 million of all deaths globally in 2019

VR/AR Applications for Training and Healthcare

In this episode of Impetus Digital's Fireside Chat, Natalie Yeadon, Co-Founder and CEO of Impetus Digital sits down with Mike Waldron, who is the CEO and Co-Founder of Propel VR....

Impetus Digital

- PMLiVE

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

The companies have also submitted an application to the EMA for this age group

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how #innovative medical devices and software can improve...

Impetus Digital

- PMLiVE

JCVI recommends spring COVID-19 booster for those at highest risk

Eligible individuals will be offered the booster around six months after their previous dose

- PMLiVE

WHO countries begin negotiations on global pandemic preparedness agreement

The discussions will continue over the next year until a final draft is made in 2024

Streamlining Healthcare Delivery Through Digital Care Journeys

Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, explores how technology and “Digital Care Journeys” can help hospitals reduce the surgical backlog for high-volume procedures like hip and knee replacements,...

Impetus Digital

- PMLiVE

Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children

The vaccine is already authorised as the third of a three-dose primary series in this age group

- PMLiVE

FDA authorises first at-home COVID-19 and flu test for emergency use

The single-use test uses nasal swab samples and provides results in about 30 minutes

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links